Biocept Overview

  • Year Founded
  • 1997

Year Founded

  • Status
  • Public

  • Employees
  • 78

Employees

  • Stock Symbol
  • BIOCQ

Stock Symbol

Biocept General Information

Description

Biocept Inc develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. In addition to its portfolio of blood-based liquid biopsy assays, Biocept has developed the CNSide cerebrospinal fluid assay that detects cancer that has metastasized to the central nervous system. Biocept's patented Target Selector technology captures and quantitatively analyzes CSF tumor cells for tumor-associated molecular markers, using technology first developed for use in blood. It is also leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 9955 Mesa Rim Road
  • San Diego, CA 92121
  • United States
+1 (858)
Primary Industry
Laboratory Services (Healthcare)
Other Industries
Other Pharmaceuticals and Biotechnology
Stock Exchange
PINX
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 9955 Mesa Rim Road
  • San Diego, CA 92121
  • United States
+1 (858)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Biocept Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$263.00 1.85K -$48.35

Biocept Financials Summary

In Thousands,
USD 		TTM 30-Jun-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020
EV 6,587 3,282 38,818 45,328
Revenue 2,269 25,858 61,249 27,461
EBITDA (28,709) (30,241) (879) (16,570)
Net Income (30,608) (32,087) (2,824) (17,807)
Total Assets 22,103 30,873 60,417 47,453
Total Debt 11,591 12,109 12,673 12,229
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Biocept Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Biocept‘s full profile, request access.

Request a free trial

Biocept Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Biocept Inc develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable i
Laboratory Services (Healthcare)
San Diego, CA
78 As of 2023

Lakewood, CO
 

South Plainfield, NJ
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Biocept Competitors (44)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
TerumoBCT Formerly PE-Backed Lakewood, CO
Admera Health Venture Capital-Backed South Plainfield, NJ
GeneCast Biotechnology Private Equity-Backed Wuxi, China
Ambry Genetics Private Equity-Backed Aliso Viejo, CA
Exagen Formerly VC-backed Vista, CA
You’re viewing 5 of 44 competitors. Get the full list »

Biocept Patents

  • 118

    Total Documents Applications and Grants

  • Total Patents Families

  • 55

    Granted

  • 6

    Pending

  • Expiring in next 12 mo

Biocept Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4244236-A1 Pathogen inactivating and nucleic acid stabilization media for microorganism collection and transport Pending 11-Nov-2020
JP-2022137291-A Methods for detecting nucleic acid sequence variants Pending 04-May-2011
JP-2020202831-A Methods for detecting nucleic acid sequence variants Active 04-May-2011
JP-2018138041-A Methods for detecting nucleic acid sequence variants Active 04-May-2011
EP-2705162-B1 Methods for detecting nucleic acid sequence variants Active 04-May-2011 C12Q1/6844
To view Biocept’s complete patent history, request access »

Biocept Executive Team (23)

Name Title Board Seat
Philippe Marchand Ph.D Chief Operating Officer, Operations
Darrell Taylor Chief Legal Officer and Chief Compliance Officer and Corporate Secretary
Rob Walsh Vice President & Controller
Hendrick Edwin Chief Commercial Officer
Faye Wilson Chair of Audit Committee & Board Member
You’re viewing 5 of 23 executive team members. Get the full list »

Biocept Board Members (19)

Name Representing Role Since
Faye Wilson Biocept Chair of Audit Committee & Board Member
M. Wilson Self Board Member
You’re viewing 2 of 19 board members. Get the full list »

Biocept Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Biocept FAQs

  • When was Biocept founded?

    Biocept was founded in 1997.

  • Who is the founder of Biocept?

    Soonkap Hahn is the founder of Biocept.

  • Where is Biocept headquartered?

    Biocept is headquartered in San Diego, CA.

  • What is the size of Biocept?

    Biocept has 78 total employees.

  • What industry is Biocept in?

    Biocept’s primary industry is Laboratory Services (Healthcare).

  • Is Biocept a private or public company?

    Biocept is a Public company.

  • What is Biocept’s stock symbol?

    The ticker symbol for Biocept is BIOCQ.

  • What is the current market cap of Biocept?

    The current market capitalization of Biocept is $263.00.

  • What is Biocept’s current revenue?

    The trailing twelve month revenue for Biocept is $2.27M.

  • Who are Biocept’s competitors?

    TerumoBCT, Admera Health, GeneCast Biotechnology, Ambry Genetics, and Exagen are some of the 44 competitors of Biocept.

  • What is Biocept’s annual earnings per share (EPS)?

    Biocept’s EPS for 12 months was -$48.35.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »